Cover Image

A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactions

Abstract Dasatinib, a second‐generation tyrosine kinase inhibitor, is approved for treating chronic myeloid and acute lymphoblastic leukemia. As a sensitive cytochrome P450 (CYP) 3A4 substrate and weak base with strong pH‐sensitive solubility, dasatinib is susceptible to enzyme‐mediated drug-drug in...

Full description

Saved in:

Bibliographic Details
Main Authors:	Christina Kovar (Author), Helena Leonie Hanae Loer (Author), Simeon Rüdesheim (Author), Laura Maria Fuhr (Author), Fatima Zahra Marok (Author), Dominik Selzer (Author), Matthias Schwab (Author), Thorsten Lehr (Author)
Format:	Book
Published:	Wiley, 2024-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Physiologically based pharmacokinetic modeling of imatinib and N‐desmethyl imatinib for drug-drug interaction predictions
by: Helena Leonie Hanae Loer, et al.
Published: (2024)

Physiologically‐based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups
by: Simeon Rüdesheim, et al.
Published: (2022)

Physiologically based pharmacokinetic modeling of tacrolimus for food-drug and CYP3A drug-drug-gene interaction predictions
by: Helena Leonie Hanae Loer, et al.
Published: (2023)

Prediction of Drug-Drug-Gene Interaction Scenarios of (<i>E</i>)-Clomiphene and Its Metabolites Using Physiologically Based Pharmacokinetic Modeling
by: Christina Kovar, et al.
Published: (2022)

Physiologically‐based pharmacokinetic modeling of quinidine to establish a CYP3A4, P‐gp, and CYP2D6 drug-drug-gene interaction network
by: Denise Feick, et al.
Published: (2023)

A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug-Drug Interaction Perpetrators
by: Fatima Zahra Marok, et al.
Published: (2023)

Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions
by: Simeon Rüdesheim, et al.
Published: (2020)

Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug-Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
by: Laura Maria Fuhr, et al.
Published: (2021)

Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network
by: Fatima Zahra Marok, et al.
Published: (2021)

A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling
by: Laura Maria Fuhr, et al.
Published: (2022)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug-Drug-Gene Interaction Predictions
by: Helena Leonie Hanae Loer, et al.
Published: (2022)

Physiologically Based Pharmacokinetic Modeling to Describe the CYP2D6 Activity Score-Dependent Metabolism of Paroxetine, Atomoxetine and Risperidone
by: Simeon Rüdesheim, et al.
Published: (2022)

Data Digitizing: Accurate and Precise Data Extraction for Quantitative Systems Pharmacology and Physiologically‐Based Pharmacokinetic Modeling
by: Jan‐Georg Wojtyniak, et al.
Published: (2020)

Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates
by: Lukas Kovar, et al.
Published: (2020)

External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease
by: Christina Schräpel, et al.
Published: (2021)

Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients
by: Lukas Kovar, et al.
Published: (2020)

A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug-Drug Interaction Studies
by: Nina Hanke, et al.
Published: (2020)

Physiologically‐Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam
by: Hannah Britz, et al.
Published: (2019)

Herb-drug interaction: Effect of sinapic acid on the pharmacokinetics of dasatinib in rats
by: Mudassar Shahid, et al.
Published: (2023)

A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug-Drug-Gene Interaction Predictions
by: Denise Türk, et al.
Published: (2020)

Therapeutic Drug Monitoring and Individualized Medicine of Dasatinib: Focus on Clinical Pharmacokinetics and Pharmacodynamics
by: Shiyu He, et al.
Published: (2021)

In Vitro-In Silico Modeling of Caffeine and Diclofenac Permeation in Static and Fluidic Systems with a 16HBE Lung Cell Barrier
by: Lukas Kovar, et al.
Published: (2022)

Population Pharmacokinetics of Dasatinib in Healthy Subjects
by: Walaa B. Hassouneh, et al.
Published: (2024)

Dasatinib Nanoemulsion and Nanocrystal for Enhanced Oral Drug Delivery
by: Chuanqi Wang, et al.
Published: (2022)

A Physiology-Based Pharmacokinetic Framework to Support Drug Development and Dose Precision During Therapeutic Hypothermia in Neonates
by: Anne Smits, et al.
Published: (2020)

A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions
by: Sebastian Frechen, et al.
Published: (2021)

Formulation Characterization and Pharmacokinetic Evaluation of Amorphous Solid Dispersions of Dasatinib
by: Sathish Dharani, et al.
Published: (2022)

Dasatinib reverses drug resistance by downregulating MDR1 and Survivin in Burkitt lymphoma cells
by: Mitsuki Tabata, et al.
Published: (2020)

Physiologically‐based pharmacokinetic model of sparsentan to evaluate drug-drug interaction potential
by: Nikunjkumar K. Patel, et al.
Published: (2024)

Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug-Drug Interactions of Phenytoin
by: Leyanis Rodriguez-Vera, et al.
Published: (2023)

Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug-Drug and Drug-Disease Interactions of Apatinib
by: Hongrui Liu, et al.
Published: (2021)

Utility of Physiologically Based Pharmacokinetic Modeling to Investigate the Impact of Physiological Changes of Pregnancy and Cancer on Oncology Drug Pharmacokinetics
by: Xinxin Yang, et al.
Published: (2023)

Prediction of Pharmacokinetic Drug–Drug Interactions Involving Anlotinib as a Victim by Using Physiologically Based Pharmacokinetic Modeling
by: Bu F, et al.
Published: (2024)

Physiologically‐Based Pharmacokinetic Model‐Informed Drug Development for Fenebrutinib: Understanding Complex Drug‐Drug Interactions
by: Yuan Chen, et al.
Published: (2020)

Evaluation of drug-drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
by: Tao Ji, et al.
Published: (2022)

Physiologically Based Pharmacokinetic Modeling and Simulation in Pediatric Drug Development
by: A R Maharaj, et al.
Published: (2014)

Development of a physiologically‐based pharmacokinetic model to simulate the pharmacokinetics of intramuscular antiretroviral drugs
by: Sara Bettonte, et al.
Published: (2024)

Development of UPLC-MS/MS Method for Studying the Pharmacokinetic Interaction Between Dasatinib and Posaconazole in Rats
by: Yang S, et al.
Published: (2021)

Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models
by: Zhiheng Yu, et al.
Published: (2022)

Physiologically‐based pharmacokinetic modeling of prominent oral contraceptive agents and applications in drug-drug interactions
by: Gareth J. Lewis, et al.
Published: (2024)